Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Conclusion: Smoking is an independent poor prognostic factor of outcome in patients treated with chemotherapy and TKI. The best outcome was obtained in non-smokers treated with chemotherapy and ponatinib (5-year OS rate of 91%). Smoking mechanisms leading to this poor outcome are being studied.DisclosuresJabbour: Novartis: Research Funding; Pfizer: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Abbvie: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding. Sasaki: Otsuka Pharmaceutical: Honoraria. Ravandi: Xencor: Research Funding; Abbvie: Research Funding; Bristol-Myers Squibb: Research Funding; Sunesis: Honoraria; Jazz: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Orsenix: Honoraria; Orsenix: Honoraria; Xencor: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria; Astellas Pharmaceuticals: Consultancy, Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Macrogenix: Honoraria, Research Funding; Bristol-Myers Squibb: Research Funding; Seattle Genetics: Research Funding; Macrogenix: Honoraria, Research Funding; Sunesis: Honoraria; Jazz: Honoraria; Abbvie: Research Funding. Short: Takeda Oncology: Consultancy. Daver: ImmunoGen: Consultancy; Incyte: Consultancy; Sunesis: Consultancy; Alexion: Consultancy; Otsuka: Consultancy; Daiichi-Sankyo: Research Funding; Novartis: Consultancy; Novartis: Research Funding; ARIAD: Research Funding; Pfizer: Research Funding; K...
Source: Blood - Category: Hematology Authors: Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II Source Type: research